[Several new treatment possibilities of hereditary angio-oedema].
Hereditary angio-oedema (HAE) is a rare genetic disease caused by deficiency of complement C1 inhibitor. It is characterised by recurrent episodes of subcutaneous or submucosal oedema typically involving the extremities, bowel, face or larynx. Within the latest years it has become evident that the active mediator of HAE attacks is an increased level of bradykinin and various new treatment modalities have been developed. The aim of this paper is to give an update from the Danish HAE Comprehensive Care Centre on current treatment possibilities and address some of the challenges when diagnosing HAE.
Hudafdeling I, Odense Universitetshospital, Sdr. Boulevard 29, 5000 Odense C, Denmark. anne.aabom@ouh.regionsyddanmark.dk
Anne Louise Nørmølle
AL
Aabom
Yaseelan
Y
Palarasah
Anette
A
Bygum
D000328:Adult; D054179:Angioedemas, Hereditary / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D065094:Bradykinin B2 Receptor Antagonists; D003174:Complement C1 Inactivator Proteins / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D050718:Complement C1 Inhibitor Protein / Q000008:administration & dosage / Q000627:therapeutic use; D051056:Complement Inactivating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004890:Erythema / Q000473:pathology; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D007819:Laryngeal Edema / Q000209:etiology; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D043782:Receptor, Bradykinin B2 / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D065094:Bradykinin B2 Receptor Antagonists; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D051056:Complement Inactivating Agents; D010455:Peptides; D043782:Receptor, Bradykinin B2; D011994:Recombinant Proteins; C469952:SERPING1 protein, human; C511194:ecallantide; C571093:conestat alfa; C065679:icatibant; D007610:Kallikreins; D001920:Bradykinin